Yamaoka K - Search Results

1

Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database.

Fujiwara M, Ikesue H, Yamaoka K, Uchida M, Uesawa Y, Muroi N, Shimizu T. Fujiwara M, et al. Among authors: yamaoka k. In Vivo. 2025 Jan-Feb;39(1):396-403. doi: 10.21873/invivo.13841. In Vivo. 2025. PMID: 39740899 Free PMC article.

2

Comprehensive Analysis of Ixazomib-Induced Adverse Events Using the Japanese Pharmacovigilance Database.

Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Yamaoka K, et al. Oncology. 2022;100(7):413-418. doi: 10.1159/000524806. Epub 2022 May 3. Oncology. 2022. PMID: 35504255

3

Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset.

Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Yamaoka K, et al. Life (Basel). 2022 Aug 31;12(9):1355. doi: 10.3390/life12091355. Life (Basel). 2022. PMID: 36143391 Free PMC article.

4

The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER.

Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Shimizu T. Yamaoka K, et al. In Vivo. 2023 Jan-Feb;37(1):345-356. doi: 10.21873/invivo.13085. In Vivo. 2023. PMID: 36593055 Free PMC article.

5

Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.

Yamaoka K, Fujiwara M, Uchida M, Uesawa Y, Muroi N, Shimizu T. Yamaoka K, et al. Oncology. 2023;101(10):664-674. doi: 10.1159/000531390. Epub 2023 Jun 6. Oncology. 2023. PMID: 37279701

6

Disproportionality Analysis of Stomatitis Associated with Anticancer Drugs Using the Japanese Adverse Drug Event Report Database.

Hosonaka K, Yamaoka K, Ikeda N, Uchida M, Uesawa Y, Takahashi K, Shimizu T. Hosonaka K, et al. Among authors: yamaoka k. Oncology. 2024;102(9):810-818. doi: 10.1159/000535331. Epub 2024 Jan 10. Oncology. 2024. PMID: 38198784

7

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma.

Yamaoka K, Irie K, Hiramoto N, Hirabatake M, Ikesue H, Hashida T, Shimizu T, Ishikawa T, Muroi N. Yamaoka K, et al. Invest New Drugs. 2023 Oct;41(5):761-767. doi: 10.1007/s10637-023-01392-1. Epub 2023 Sep 18. Invest New Drugs. 2023. PMID: 37721661 Free PMC article.

8

Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.

Ikesue H, Yamaoka K, Matsumoto A, Hirabatake M, Muroi N, Yamasaki T, Kawakita M, Hashida T. Ikesue H, et al. Among authors: yamaoka k. Cancer Chemother Pharmacol. 2022 Jun;89(6):833-838. doi: 10.1007/s00280-022-04408-4. Epub 2022 Mar 7. Cancer Chemother Pharmacol. 2022. PMID: 35254504 Free PMC article.

9

Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.

Mabuchi M, Ueda M, Yoshida Y, Horiike K, Yamaoka K, Nakao S, Shimizu T, Ueda Y, Tsujikawa K, Tanaka A. Mabuchi M, et al. Among authors: yamaoka k. Anticancer Res. 2017 Apr;37(4):1665-1676. doi: 10.21873/anticanres.11496. Anticancer Res. 2017. PMID: 28373427

10

Cerebrospinal fluid concentration of foscarnet in patients with HHV-6 encephalitis after haematopoietic stem cell transplantation.

Irie K, Hiramoto N, Yamaoka K, Fuckushima S. Irie K, et al. Among authors: yamaoka k. J Antimicrob Chemother. 2023 Jun 1;78(6):1549-1551. doi: 10.1093/jac/dkad117. J Antimicrob Chemother. 2023. PMID: 37071595 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

979 results

Search Page

Filters